Inspire Begins Phase III Trial Of Denufosol Tetrasodium For Cystic Fibrosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm must complete the 48-week study before submitting an NDA for inhaled denufosol.
You may also be interested in...
Inspire To Submit Additional Data For Dry Eye Treatment
Ongoing discussions between the company and FDA regarding diquafosol may take several months, Inspire says.
Inspire's Denufosol Moves To Phase III For Cystic Fibrosis
The clinical program will include two pivotal efficacy studies and long-term carcinogenicity study.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.